Compare iShares MSCI Japan ETF (EWJ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI Japan ETF trades at $91.91, while Regeneron Pharmaceuticals Inc trades at $677.44 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while iShares MSCI Japan ETF pays none, and iShares MSCI Japan ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWJ | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $96.97 | $812.27 |
52-Week Low | $71.81 | $542.52 |
Market Cap | — | $69.66B |
Enterprise Value | — | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $91.92, down 2.1% on the day, with a bullish technical signal from moving averages but neutral oscillators. The fund provides exposure to Japanese equities amid a weakening yen, with news highlighting potential currency intervention by Japanese authorities and domestic investment pushes. Recent performance reflects Nikkei 225 volatility, trading near all-time highs before recent pullbacks.
Outlook hinges on yen stability and Japanese economic policies, with opportunities in hedged alternatives to mitigate currency risk. Risks include FX volatility, geopolitical tensions, and Japan's debt burden. Analyst sentiment is mixed, focusing on currency dynamics and equity market resilience.
Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.
Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
